JSPR vs. NMRA, KALV, AURA, ORGO, ETON, VALN, PRME, KRRO, RGNX, and CTNM
Should you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include Neumora Therapeutics (NMRA), KalVista Pharmaceuticals (KALV), Aura Biosciences (AURA), Organogenesis (ORGO), Eton Pharmaceuticals (ETON), Valneva (VALN), Prime Medicine (PRME), Korro Bio (KRRO), REGENXBIO (RGNX), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry.
Jasper Therapeutics vs.
Neumora Therapeutics (NASDAQ:NMRA) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability, community ranking and analyst recommendations.
Jasper Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.
47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are held by institutional investors. 26.4% of Neumora Therapeutics shares are held by insiders. Comparatively, 2.7% of Jasper Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Jasper Therapeutics' return on equity of -67.64% beat Neumora Therapeutics' return on equity.
Jasper Therapeutics received 19 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. Likewise, 89.80% of users gave Jasper Therapeutics an outperform vote while only 89.29% of users gave Neumora Therapeutics an outperform vote.
In the previous week, Neumora Therapeutics had 2 more articles in the media than Jasper Therapeutics. MarketBeat recorded 4 mentions for Neumora Therapeutics and 2 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.89 beat Neumora Therapeutics' score of 0.06 indicating that Jasper Therapeutics is being referred to more favorably in the news media.
Neumora Therapeutics presently has a consensus target price of $16.50, suggesting a potential upside of 704.88%. Jasper Therapeutics has a consensus target price of $67.75, suggesting a potential upside of 1,129.58%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than Neumora Therapeutics.
Neumora Therapeutics has a beta of 2.71, suggesting that its stock price is 171% more volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500.
Summary
Jasper Therapeutics beats Neumora Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Jasper Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jasper Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:JSPR) was last updated on 1/21/2025 by MarketBeat.com Staff
Free JSPR Stock Alerts